December 3-4, 2015 | Philadelphia, PA
You know it and have read it here before: pharma leaders in data, HEOR, and market access need to come together to collaborate with health systems and physician leaders.
The 4th annual Real World Evidence & Market Access Summit on December 3-4 will be big pharma’s last opportunity to shape the evidence strategy for 2016 – and the only one with all stakeholders present.
Here’s why the event is a must-attend:
- Payer/provider panel discussions: Talk risk-based contracting and discover directly how access and formulary decisions are evolving from the customer point of view. Hear from Jerrold Penso, Chief Medical & Quality Officer, AMGA and Steve Chick, Vice President, Comprehensive Health Insights, Humana
- 15+ major health systems: Explore new opportunities for data and evidence collaboration and meet directly with health systems. Engage with change-makers such as Eric Newman, Chief of Specialty Care Innovation & Integration, Geisinger
- 1 event, 5 tailor-made tracks: Choose from a menu of opportunities – plan each day around the insights that matter most to you (real world analytics, HEOR, market access, organizer customer groups and data partnerships)
Attendees learn as much from the world-class speaking faculty as they learn from their peers. Recent registrants include:
- Clément François, Vice President, HEOR, US Lundbeck
- Faisal Mehmud, Vice President, Medical Affairs, Novartis Oncology
- John Hernandez, Global Vice President, HEOR, Abbott
- Garret Ingram, Vice President, Head of US Market Access, Sanofi
- David Tomala, Senior Director, Advanced Analytics, Express-Scripts
- Mark Weiner, Chief Medical Information Officer, Temple University Health System
We’ve already confirmed dozens senior participants from: Novartis / Otsuka/ Janssen Pharmaceuticals/ Hoffmann-La Roche/ UCB/ Bayer/ Novo Nordisk/ Daiichi Sankyo/ Genentech/ AbbVie/ Millennium / DSI/ Takeda/ Oracle / J&J/ Mount Sinai/ Geisinger/ Pfizer/ EMD Serono/ Shire / SAS/ Eisai…
For those who like to stay ahead of the curve in showing drug value, this is a must-attend.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.